Neopterin-inhibitor of dihydrofolate reductase and hypothetical action in the human body

Jan Olszewski, Włodzimierz Samborski, Sławomir Bartkowiak


Concentration of neopterin  in the organism increases during many diseases and therefore it is used as a marker to assess the severity of these disease, applied treatment severity, oxidative stress and the cellular immune response.  In this paper we attempt to determine the new properties of neopterin and  its hypothetical role in DHFR activity in the human body. During the study we worked with neopterin by SIGMA, purity ≥ 98% (HPLC), and a set of reagents to determine the activity of dihydrofolate reductase. The study was performed using a spectrophotometer at a wavelength of  λ = 340 nm. The obtained results have confirmed that neopterin inhibits the activity of DHFR, both when it is fully dissolved in 1 N HCl as a suspension in a buffer (pH = 7.5) and as a supernatant. DHFR inhibition depends on the neopterin concentration in the reaction mixture.  The results of our research and our discovery of new properties of neopterin as a DHFR inhibitor allow us to determine the hypothetical importance of neopterin in the body's defence system.


neopterin;inhibition of DHFR;folate metabolism;defence mechanisms

Full Text:



Rembold, H. and Buschmann, L. 1963. Struktur und Synthese des Neopterins. Chem. Ber. 96, 1406-1414. [2] Wachter, H., Grassmayr, K., Gutter, W., Hausen, A., Sallaberger, G. and Gabl, F. 1971. Urinary low molecular weight products in neoplasia. Br. Med. J. 2, 322-323. [3] Gavryushin, V., Auksorius, E., Fuchs, D. and Vaitkuvienė, A. 2002. The role of neopterin in the fluorescence investigations of bio tissue pathology. Lithuanian J. Phys. 42, 111-118. [4] Werner, R., Bichler, A., Daxenbichler, G., Fuchs, D., Fuith, L.C., Hausen, A., Hetzel, H., Reibnegger, G. and Wachter,H. 1987. Determination of neopterin in serum and urine. Clin. Chem. 33, 62-66. [5] Gruber, G., Lirk, P., Amann, A., Keller, C., Schobersberger, W., Hoffmann, G., Fuchs, D. and Rieder, J. 2002 Neopterin as a marker of immunostimulation: an investigation in anaesthetic workplaces. Anaesthesia. 57, 747-750. [6] Schroecksnadel, K., Murr, C. , Winkler, C., Wirleitner, B., Fuith, L.C. and Fuchs D. 2004. Neopterin to monitor clinical pathologies involving interferon-gamma production. Pteridines. 15, 75-90. [7] Murr, C., Widner, B., Wirleitner, B. and Fuchs, D. 2002. Neopterin as a Marker for Immune System Activation. Curr. Drug Metab. 3(2), 175-187. [8] Wirleitner, B., Reider, D., Ebner, S., Böck, G., Widner, B., Jaeger, M., Schennach, H., Romani, N. and Fuchs D. 2002. Monocyte-derived dendritic cells release neopterin. J. Leuk. Biol. 72, 1148-1153. [9] Stahl-Hennig, C., Fendrich, C., Lüke, W., Widner, B, Hunsmann, G. and Fuchs D. 2002. Urinary neopterin indicates early infecion and disease progression: model studies with simian and human immunodeficiency viruses in macaques. Pteridines 13, 1-8. [10] Grebe, S.O. and Mueller, T.F. 2002. Immune monitoring in organ transplantation using neopterin.Curr.Drug Metab. 3, 189-202. [11] Weimer, R., Süsal, C., Yildiz, S., Staak, A., Pelzl, S., Renner, F., Dietrich, H., Daniel, V., Kamali-Ernst, S.,Ernst, W., Padberg, W. and Opelz, G. 2006. Post-transplant sCD-30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am. J. Transplant. 6(8), 1865-1874. [12] Plata-Nazar, K. and Jankowska, A. 2011. Clinical usefulness of determining the concentration of neopterin. Pteridines 22(3), 77-89. [13] Oxenkrug, G.F., Requintina, P.J., Mikolich, D.L., Ruthazer, R., Viveiros, K., Lee, H. and Summergrad P.2012. Neopterin as a Marker of Response to Antiviral Therapy in Hepatitis C Virus Patients. Hepat. Res. Treat. 2012, 1-4. [14] Zheng, B., Cao ,K.Y., Chan, C.P.Y., Choi, J.W.Y., Leung, W., Leung, M., Duan, Z.H., Gao, Y., Wang, M.,Di, B., Hollidt, J.M., Bergmann, A., Lehmann, M., Renneberg, I., Tam, J.S.L., Chan, P.K.S.,Cautherley, G.W.H., Fuchs, D. and Renneberg R. 2005. Serum neopterin for early assessment of severe acute respiratory syndrome. Clin. Immunol. 116(1), 18-26. [15] Yildirim, Y., Gunel, N., Coskun, U., Pasaoglu, H., Aslan, S. and Cetin, A. 2008. Serum neopterin levels in patients with breast cancer. Med. Oncol. 25(4), 403-407. [16] Piecuch, J., Rudzki, M., Orkisz ,W., Swietochowska, E., Wielkozynski, T., Waniczek, D., Arendt, J.,Sosada, K., Zurawinski, W. 2008. Ladny, J.R. Neopterin-a potential factor differentiation between pancreatic cancer and chronic pancreatitis. Hepatogastroenter. 55(81), 258-261. [17] Nicola, F., Markus, A., Gunther, B.and Werner, K. 2011. Expression of Neopterin and Chemokines in Rheumatoid Arthritis and Cardiovascular Disease. Pteridines 22, 7-12. [18] Sucher, R., Schroecksnadel, K., Weiss, G., Margreiter, R., Fuchs, D. and Brandacher, G. 2010.Neopterin, a prognostic marker inhuman malignancies. Cancer Lett. 287, 13-22. [19] Cincibuch, J., Cwiertka, K., Procházková-Studentová, H., Zezulová, M., Neoral, C., Kalábová, H.Krcmová, L., Malírová, E., Solichová, D. and Melichar B. 2012. Prognostic Significance of Serum Neopterin in Patients with Esophageal Carcinoma. Pteridines 23, 22-26. [20] Czeczot, H. 2008. Folic acid physiology and pathology. Postępy Hig. Med. Dośw. 62, 405-419.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2007 Journal of Advances in Biology - All Rights Reserved